Ipsen and Galderma announced that they had expanded their distribution agreement for Ipsen's Dysport neurotoxin to some Asia-Pacific markets. Under the new terms, Galderma obtains exclusive rights to develop and distribute Dysport for aesthetic indications in the region. Both have also extended their collaboration in research and development, under which Galderma will fund Ipsen's ongoing Phase III trial of Dysport in glabellar lines in China.

In exchange, Galderma will acquire regulatory filing and distribution rights on the product in China. In addition, Ipsen will buy the intellectual property rights on Galderma's liquid toxin in the Asia-Pacific.